Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $13.80.

A number of equities analysts recently weighed in on OBIO shares. Barclays raised their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Chardan Capital reiterated a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, November 13th. Finally, TD Cowen started coverage on Orchestra BioMed in a research report on Wednesday, December 10th. They issued a “buy” rating on the stock.

Institutional Trading of Orchestra BioMed

Institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. bought a new stake in Orchestra BioMed in the 4th quarter valued at $38,000. Catalyst Funds Management Pty Ltd bought a new stake in Orchestra BioMed during the 2nd quarter valued at about $31,000. Creative Planning bought a new stake in shares of Orchestra BioMed during the second quarter valued at approximately $40,000. XTX Topco Ltd purchased a new stake in Orchestra BioMed in the second quarter worth about $45,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Orchestra BioMed in the 4th quarter worth approximately $76,000. Hedge funds and other institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Price Performance

OBIO stock opened at $3.92 on Friday. The company has a fifty day moving average price of $4.16 and a 200-day moving average price of $3.66. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.72 and a current ratio of 4.73. The company has a market capitalization of $221.34 million, a P/E ratio of -2.15 and a beta of 0.61. Orchestra BioMed has a 52-week low of $2.20 and a 52-week high of $5.42.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.